Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.

Venetsanopoulou I Aliki Paraskevi Vasileios Voulgari Alexandros A Drosos

Published in: Expert review of clinical immunology (2022)

TNFi and JAKi are particularly useful in treating inflammatory arthropathies. Both drug categories are recommended by ACR and EULAR institutions in RA patients suffering from moderate to severe disease. Safety data in long-term studies are required to determine the optimal benefit to the risk profile of JAKi use.

Keyphrases

rheumatoid arthritis
end stage renal disease
disease activity
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
oxidative stress
early onset
electronic health record
big data
tyrosine kinase
machine learning
deep learning
idiopathic pulmonary fibrosis